

Amendments to Claims

1. (Currently Amended) A method of detecting the presence of an oncogenic human papilloma virus (HPV) protein in a sample, said method comprising:
 - contacting a sample suspected of containing an oncogenic HPV E6 protein with a PDZ domain polypeptide; and
 - detecting any binding of said oncogenic HPV E6 protein in said sample to said PDZ domain polypeptide;
 - wherein binding of said oncogenic HPV E6 protein to said PDZ domain polypeptide indicates the presence of an oncogenic HPV E6 protein in said sample and
 - wherein said PDZ domain polypeptide is less than 1000 amino acid in length and comprises the amino acid sequence of MAGI-1 PDZ domain 2.
2. (Cancelled)
3. (Previously Presented) The method of claim 1, wherein said PDZ domain peptide binds to HPV E6 protein encoded by HPV strains 16, 18, and 45.
4. (Original) The method of claim 1, wherein sample is contacted with multiple PDZ domain polypeptides.
5. (Original) The method of claim 1, wherein said PDZ protein is a fusion protein.
6. (Currently Amended) A system for detecting the presence of an oncogenic human papilloma virus (HPV) polypeptide in a sample, said method comprising:
 - a first and a second binding partner for an oncogenic HPV E6 polypeptide,
 - wherein said first binding partner is a PDZ domain ~~protein~~ polypeptide and at least one of said binding partners is attached to a solid support and

wherein said PDZ domain polypeptide is less than 1000 amino acid in length and
comprises the amino acid sequence of MAGI-1 PDZ domain 2.

7. (Original) The system of claim 6, wherein said second binding partner is an antibody
against said oncogenic HPV E6 polypeptide.

8. (Original) The system of claim 7, wherein at least one of said binding partners is labeled.

9. (Cancelled)

10. (Currently Amended) A method for determining if a subject is infected with an oncogenic
strain of human papilloma virus (HPV), said method comprising:

detecting the presence of oncogenic HPV E6 protein in a sample from said subject using an
oncogenic HPV E6 protein-binding PDZ ~~protein~~ polypeptide,

wherein the presence of oncogenic HPV E6 protein indicates that the subject is infected
with an oncogenic strain of HPV and

wherein said PDZ domain polypeptide is less than 1000 amino acid in length and
comprises the amino acid sequence of MAGI-1 PDZ domain 2.

11. (Original) The method of claim 10, wherein said detecting step further comprises detecting
the presence of said oncogenic HPV E6 protein using an antibody that specifically binds to said
oncogenic HPV E6 protein.

12. (Original) The method of claim 10, wherein said sample is a cervical scrape, biopsy, or
lavage.

13. (Original) The method of claim 12, wherein said method is an ELISA or a sandwich assay.

14. (Original) The method of claim 10, wherein said sample is prepared in the presence of a
protease inhibitor.

15. (Current Amended) The method of claim 10, wherein said method is [[a]] performed as a part of a test for cervical cancer.
16. (Withdrawn) A kit for testing for the presence of oncogenic HPV E6 protein, the kit comprising first and second binding partners for said oncogenic HPV E6 protein, wherein said first binding partner is a PDZ domain protein.
17. (Withdrawn) The kit of claim 14, wherein at least one of the binding partners is attached to a solid support.
18. (Withdrawn) The kit of claim 16, wherein said solid support is a test strip.
19. (Withdrawn) The kit of claim 16, wherein said second binding partner is an antibody.
20. (Withdrawn) The kit of claim 16, further comprising instructions for detecting the presence of an oncogenic HPV E6 protein in a sample.

Please add the following new claims:

21. (New) The method of claim 1, 6, 10, wherein said PDZ domain polypeptide is less than 500 amino acid in length.
22. (New) The method of claim 1, 6, 10, wherein said PDZ domain polypeptide is less than 200 amino acid in length.
23. (New) The method of claim 1, 6, 10, wherein said PDZ domain polypeptide is less than 100 amino acid in length.

24. (New) A method of detecting the presence of an oncogenic human papilloma virus (HPV) protein in a sample, said method comprising:

contacting a sample suspected of containing an oncogenic HPV E6 protein with a fusion protein comprising a heterologous domain and a PDZ polypeptide comprising MAGI-1 PDZ domain 2; and

detecting binding of said oncogenic HPV E6 protein in said sample to MAGI-1 PDZ domain 2 in said fusion protein, wherein binding of said oncogenic HPV E6 protein to MAGI-1 PDZ domain 2 in said fusion protein indicates the presence of an oncogenic HPV E6 protein in said sample.

25. (New) The method of claim 24, wherein PDZ polypeptide is less than 200 amino acid in length.

26. (New) The method of claim 1, 6, 10 or 24, wherein the oncogenic HPV is selected from the group consisting of HPV strain 16, 18, 31, 35, 30, 39, 45, 51, 52, 56, 59, 58, 33, 66, 68, 69, 26, 53, 66, 73, and 82.